Navigation Links
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Date:7/7/2008

Expanded HCV Development Presence Includes ANA598 and ANA773 Acting via

Independent but Potentially Complementary Mechanisms

Conference Call Today at 2:00 PM PDT

SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it is resuming clinical investigation of the Toll-Like Receptor-7 (TLR7) mechanism for the treatment of chronic hepatitis C. Based on preclinical pharmacology testing and the results of completed 13-week GLP animal toxicology studies, Anadys has received clearance to initiate a clinical trial of ANA773, the Company's oral TLR7 agonist prodrug, under a clinical trial application (CTA) in the Netherlands. Following initial dosing in healthy volunteers, this trial will explore every-other-day dosing over 28 days in HCV patients. Anadys also continues to enroll patients in a separate Phase I clinical trial of ANA773 in oncology that is ongoing under an IND in the United States.

"In an extensive preclinical program conducted with ANA773, we have previously shown that the profile of immune stimulation resulting from TLR7 activation can be dramatically modulated by altering the schedule of administration," said James Freddo, M.D., Anadys' Chief Medical Officer. "Now, results of toxicology studies employing every-other-day dosing of ANA773 have shown that we can achieve desired levels of immune stimulation sustained over 13 weeks without adverse toxicology findings. The favorable toxicology profile seen to date, coupled with the stable induction of interferon-alpha dependent responses when ANA773 is dosed every other day over 13 weeks, have convinced us that ANA773 has the potential to demonstrate benefit in patients infected with HC
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
2. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 Cogentix Medical, Inc. (NASDAQ: ... urology market, will release financial results for the first quarter ... the market close on Monday, August 10, 2015. ... to discuss these results on Monday, August 10, 2015 at ... Kill , President and Chief Executive Officer, and Brett ...
(Date:7/29/2015)... Calif. , July 29, 2015  AcelRx ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... on Monday, Aug 3rd, 2015. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on Aug ...
(Date:7/29/2015)... MOUNTAIN VIEW, Calif. , July 29, 2015 /PRNewswire/ ... in the growth strategy of pharmaceutical firms in ... . The realization is that an effective working ... sales, pricing pressures and patent cliffs. Big pharma companies ... bolster returns. Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO ...
Breaking Medicine Technology:Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
... Nov. 20 Smith & Nephew ( SNN, LSE: SN) ... technology development contract with the United States Department of Defense ... system intended to revolutionize the treatment of the limbs of ... Advanced Research Projects Agency (DARPA), the central research and development ...
... 19 In response to an ever-increasing number of ... involving 24 countries, was coordinated by INTERPOL and the ... to highlight the dangers of buying medicines online. , ... of arrests and the seizure of thousands of potentially ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2
(Date:7/29/2015)... ... 2015 , ... The New Foundation AZ recently started a massive ... cost the 501(c) organization nearly $1 million, will both update the facilities’ design and ... it down to the studs,” said Geraldine Leary, the New Foundation AZ chief executive ...
(Date:7/29/2015)... ... 29, 2015 , ... National non-profit World T.E.A.M. Sports announced ... employee benefits and asset management, has joined as presenting sponsor for the inaugural ... Charlotte, North Carolina on October 2-4, 2015. , Hosted at the U.S. ...
(Date:7/29/2015)... Indiana (PRWEB) , ... July 29, 2015 , ... Indiana ... It is also the home of Zerorez Indianapolis, which plans to expand across ... late 2013. “2015 is our second full year in business and we should double ...
(Date:7/29/2015)... Antonio, TX (PRWEB) , ... July 29, 2015 ... ... by a board-certified gastroenterologist, has launched a chewable version of its EndoMune Jr. ... to be a tasty, all-natural supplement that children can enjoy to maintain a ...
(Date:7/29/2015)... TN (PRWEB) , ... July 29, 2015 , ... ... Value-Added Solutions Group, which Breckheimer oversees. In her role, Powers is responsible for ... Upon making the announcement, Breckheimer commented, “Gina’s track record as an effective leader ...
Breaking Medicine News(10 mins):Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 2Health News:EndoMune Advanced Probiotic adds Chewable Tablet for Kids to Product Line 3Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3
... stroke, irrespective of traditional vascular risk factors, according to ... partly heritable. However, the importance of genetic and environmental ... the Stroke Prevention Research Unit at the Radcliffe Infirmary, ... patients who had an ischaemic stroke or transient ischaemic ...
... shown that the chemical language with which neurons communicate ... developing nervous system. The findings suggest that modification of ... a wide range of brain disorders. ,In the ... of the journal Proceedings of the National Academy of ...
... Saha and collaborators have found that the genetically engineered ... sources could set the stage for a new, biobased ... chewing gum, toothpaste, mouthwash and other products. ... and even to some degree by the human body. ...
... Medical School Researchers are developing the first of the generation ... the hospital superbug MRSA that lives in the nose. ... by standard antibiotics because the bacteria have developed a resistance ... scheduled for testing in humans next year and may be ...
... medical park and a vaccine park in Chennai soon to ... for research into new vaccines, said Health Minister Anbumani Ramadoss. ... manufacture medical equipment for the country, the vaccine park will ... ,"The medical park will be built on 300 acres of ...
... A new study that takes a rare look at the ... settings shows that when older adults go to bed lonely, ... after waking the next morning. ,Elevated levels of ... other health problems when chronic -- actually cue the body ...
Cached Medicine News:Health News:Electrical Activity Alters Language Used By Nerve Cells 2Health News:Electrical Activity Alters Language Used By Nerve Cells 3Health News:India to set up medical and vaccine parks: Ramadoss 2Health News:Adults Who Go to Bed Lonely Get Stress Hormone Boost Next Morning 2Health News:Adults Who Go to Bed Lonely Get Stress Hormone Boost Next Morning 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: